-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 6, Huahai Pharmaceutical issued an announcement saying that the abbreviated new drug application for metoprolol succinate sustained-release tablets and silodosin capsules submitted by the company to the US FDA has been approved
.
1.
Metoprolol succinate sustained-release tablets
Metoprolol succinate sustained-release tablets
Metoprolol succinate extended-release tablets are mainly used for the treatment of hypertension, angina pectoris, and symptomatic stable chronic heart failure with abnormal left ventricular systolic function
.
Metoprolol succinate extended-release tablets were developed by AstraZeneca and first launched in 1992
Up to now, the company has invested about 6.
37 million yuan in research and development on the metoprolol succinate sustained-release tablet project
.
2.
Silodosin Capsules
Silodosin Capsules
Silodosin Capsules are primarily used to improve symptoms and signs of benign prostatic hyperplasia (BHP)
.
Silodosin capsules were developed by Allergan and were first launched in 2008
Up to now, the company has invested about 4.